Oncology Division
Alphabetical list (active faculty):   
Jason D. Weber

Jason D. Weber, PhD


Department of Medicine

Oncology Division

Molecular Oncology

Department of Cell Biology & Physiology

Research Interests

  • Cell cycle
  • Tumor suppressors
  • Oncogenes


  • 314-747-3896 (office)
  • 314-747-3898 (lab)
  • 314-747-2797 (fax)
  • Division of Oncology
    Campus Box 8069
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • BJC Institute of Health, Room 7609 (lab)


Lab Overview

The goal of my laboratory is to understand the basic mechanisms behind tumor cell growth and proliferation. Cellular growth involves the production of ribosomes and translation of existing mRNAs into proteins. Numerous projects in the lab are aimed at understanding these basic processes and how they might impact tumor growth and progression. I have a broad background in molecular and cellular biology with an emphasis on tumor cell biology. I have recently expanded my research to understand the processes of cell growth signaling, ribosome biogenesis and mRNA translation in breast cancer. We have begun to identify interaction networks with these pathways using genetic, biochemical, and proteomic approaches. As PI on numerous grants, my lab laid the foundation for how major tumor suppressors prevent tumor formation by targeting cellular growth pathways. We have been a leader in the field of ARF tumor suppressor biology since its discovery and continue to seek information on how ARF functions in collaboration with p53.

Breast Cancer Projects

Triple negative breast cancer (TNBC) has become a frequently used descriptor for those cancers that are estrogen receptor, progesterone receptor and HER2 negative. This breast cancer subtype remains a challenge to clinicians, laboratory investigators, and patients due to its disproportionate number of breast cancer deaths and its lack of an established therapeutic target. TNBC is an aggressive disease where overall survival, regardless of stage, is poor when compared to other subtypes. While TNBC certainly shows significant overlap with basal-type and BRCA1-related breast cancers, this overlap is not complete. Moreover, we can now appreciate that the TNBC subtype can be further divided into subgroups based on expression signatures, resulting in distinct subgroups with putative molecular targets. The identification of new subgroups within TNBC, based on novel biomarkers or unique biology, will thus be critical in our ability to identify proper molecular therapeutic targets for these patients. We have recently observed deletion or repression of the CDKN2A (Arf) tumor suppressor locus in nearly all of the mutant p53 TNBCs we have analyzed, suggesting that these two tumor suppressors might act in concert to prevent aggressive TNBC. Consistent with this finding, mouse fibroblasts, mouse mammary epithelial cells (MMECs), and human mammary epithelial cells (HMECs) lacking both Arf and p53 exhibit tremendous gains in growth and proliferation. Notably, we have shown that these cells secrete more interferon-β (IFN-β) that in turn activates a canonical JAK1/STAT1-signaling cascade. Importantly, we have also observed this connection in human TNBC. Our data shows that increases in interferon signaling and subsequent downstream ISG15 expression are required to maintain the aggressive tumor characteristics of Arf/p53-null MMECs, leading us to believe that this might constitute a novel and druggable oncogenic pathway in TNBC. The ultimate goal of this work is to elucidate the mechanism by which the IFN-β pathway acts to transform cells lacking ARF and p53 tumor suppressors. Therefore, components of IFN-β signaling cascade will be potential targets for cancer treatment or diagnosis.

miRNA Projects

Drosha is an RNAse III endonuclease capable of cutting double-stranded RNAs. It is part of the microprocessor, a multi-protein complex involved in the first step of microRNA (miRNA) processing. In addition to its role in miRNA processing, Drosha also participates in the processing of ribosomal RNA (rRNA) and the destabilization of mRNAs. The ability of Drosha to regulate multiple RNA species within the cell makes it an important mediator of cellular homeostasis. Both genomic amplification and post-transcriptional overexpression of Drosha expression has been reported in multiple cancers, including breast cancer. Drosha expression has been shown to have prognostic value in some cancers while showing a strong correlation with disease progression in others. However, the mechanisms involved in the regulation of Drosha expression and how alterations in Drosha expression contribute toward tumorigenesis are not known. Recently, our lab identified a novel pathway involved in regulation of Drosha expression - the ARF tumor suppressor pathway. Under normal cellular conditions, oncogenic stimuli activate the ARF tumor suppressor pathway, which is a potent inhibitor of ribosome biogenesis. We found that loss of ARF induces Drosha protein expression by increasing Drosha mRNA translation in a selective manner. Furthermore, ARF loss also increased nucleolar localization and ribosome biogenesis functions of the Drosha binding partner, DDX5. ARF loss also stimulated a selective miRNA signature, suggesting a new role for ARF in miRNA processing pathway. The long-term goal of this work is to understand how alterations in Drosha expression contribute to tumorigenesis. Since ARF loss is a frequent occurrence in breast cancer, identifying the mechanism underlying ARF-mediated regulation of Drosha has functional relevance for understanding breast cancer biology.

NF1 Signaling Projects

Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder in which affected individuals are prone to the development of both benign and malignant tumors. Unfortunately, current therapies for these tumors heavily borrow from treatments used for sporadic cancers, and no NF1-targeted therapies have emerged as effective. Two of the most clinically challenging tumors in NF1 are the optic glioma (astrocytoma) and the malignant peripheral nerve sheath tumor (MPNST). We have previously shown that NF1-associated optic glioma and MPNST exhibit high levels of mammalian target of rapamycin (mTOR) pathway activation, such that agents that block mTOR activity inhibit Nf1-deficient cell proliferation in vitro. However, rapamycin and its analogues have not proven nearly as successful in the clinical setting, thus warranting the discovery of more refined targets in this pathway. To overcome this limitation, we have sought to identify additional novel components of the mTOR pathway deregulated in NF1-deficient nervous system cells. First, we have shown that Nf1-null astrocytes require enhanced protein synthesis in order to achieve maximal proliferation. Second, we have demonstrated that the DDX1 and DDX5 DEAD-box RNA helicases forms a complex with mTOR in astrocytes, which is increased following Nf1 gene inactivation. Third, astrocytes containing mTOR-DDX1/DDX5 complexes generate a unique profile of miRNAs and actively translating mRNAs. We believe that this novel mTOR-DDX1/5 complex signals to the microRNA and mRNA translation machinery to control astrocyte proliferation in the absence of neurofibromin and presents itself as a novel therapeutic target in NF1. Our collaborative team is ideally positioned to solve this problem, having extensive experience in the NF1 field and in applying our knowledge of mTOR signaling to the identification of relevant targets. Our established collaborative track record includes the identification of mTOR as a downstream target of neurofibromin, aberrant signaling in NF1, altered ribosome biogenesis in NF1, mTOR-directed selective mRNA translation, and abnormal DDX5 activities.